Clinical Trials Browser

Phase 2 × Macroglossia × isatuximab × Clear all

NCT03499808 2025-09-09

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Constipation, Diarrhea, Gastrointestinal Hemorrhage, Hepatomegaly, Macroglossia, Nausea, Purpura